In our continuous search for selective anticancer treatments, we have screened 65 extracts from 45 plants collected in several areas of Western Andalusia (Spain) for cytotoxic activity against lung cancer cells and lung normal cells. Active extracts were also tested against 11 cell lines from other tissues. An extract from the leaves of Tetraclinis articulata (Vahl) Mast. (Cupressaceae) showed a marked cytotoxicity (IC 50 = 0.37 ± 0.03 µg/mL) and selectivity (selectivity index = 378.3) against the lung cancer cells; cisplatin, 5-fluorouracil and an extract from the leaves of Taxus baccata L. (Taxaceae) were less cytotoxic and selective.
Introduction
Despite the recent approval of new anticancer treatments, metastasis continues to be an incurable disease for most cancer patients. The limited efficacy of the existing therapies is reflected in the poor survival rates of patients with the most common metastatic cancers [1] . For example, distant metastasis occur in 57% of patients diagnosed with lung cancer, and only 5% of them survive 5 years after diagnosis [1] . Understanding why the current treatments rarely cure patients with disseminated disease is important to discover better therapies. When one treats cancer cells with specific concentrations of the available anticancer drugs and examines the cells under the microscope, one generally observes a massacre. All cancer cells die in response to most treatments. However, these drugs also kill normal cells at similar concentrations. The consequence of this limited selectivity is that patients cannot receive the drug doses needed to kill all their cancer cells; such doses would also kill their normal body cells and would be lethal. Although oncology patients generally receive the maximum tolerated doses, these doses are usually insufficient to reach the drug concentrations required to eradicate their cancer cells. The surviving cancer cells continue to proliferate and eventually lead to a fatal outcome. Finding drugs with a high selectivity towards cancer cells is crucial to develop more effective treatments for patients with metastasis [2] [3] [4] .
Several plants have provided useful drugs for the treatment of a variety of cancers, including lung cancer [5] [6] [7] [8] . For example, the diterpene paclitaxel (isolated from the bark of Taxus brevifolia Nutt., Taxaceae) and their semisynthetic derivative docetaxel are FDA-approved drugs for the treatment of non-small cell lung cancer. Vinorelbine, a semisynthetic analog of the vinca alkaloids (isolated from Catharanthus roseus G. Don., Apocynaceae), is also approved for patients with this type of cancer.
Etoposide (a semi-synthetic analogue of the natural lignane podophyllotoxin, isolated from Podophyllum species, Podophyllaceae) and topotecan (an analogue of the quinoline alkaloid camptotethin, isolated from Camptotheca acuminata Decne, Nyssaceae) are approved for patients with small cell lung cancer. Because several plants have provided useful anticancer agents, we recently used lung cancer cells and lung normal cells to evaluate the selective anticancer activity of 57 extracts from plants collected in Grazalema Natural Park (Andalusia, Spain) [9] . Using a similar experimental approach, we have evaluated the selective anticancer activity of 65 extracts from 45 new plants collected in several areas of Western Andalusia, and report the results in this communication.
Material and Methods

Plant material
All plants were collected by Dr. F. García between November 2012 and April 2013 in several areas of Sevilla, Cadiz and Huelva (Andalusia, Spain). Collection was non-destructive and plat specimens (5-110g) were carefully selected to avoid any damage that could affect the conservation of any species. A voucher specimen was deposited in the herbarium at the Department of Vegetal Biology and Ecology, Faculty of Biology, University of Seville. The botanical names, plant parts and voucher specimen numbers are listed in Table 1 . Collection coordinates are provided in Table 1S (Supplementary Material).
Preparation of the extracts
Extracts were prepared within several hours after collecting the plants. Fresh plant material (5-110g) was extracted with 100-200 mL of ethanol / ethyl acetate / water (1:1:1) at 60°C for 1 hour by using an ultrasound water bath apparatus. After vacuum filtration, ethanol and ethyl acetate were eliminated in a rotary vacuum evaporator at 60°C. Finally, the remaining water solution was lyophilized to yield dried extracts. The extraction yield (%) for each extract (see identification number in Table 1 ) was: 1 (1.9%), 2 (3.0%), 3 (5.6%), 4 (4.5%), 5 (0.9%), 6 (2.9%), 7 (5.9%), 8 (4.0%), 9 (2.7%), 10 (5.5%), 11 (2.0%), 12 (2.9%), 13 (3.5%), 14 (8.5%), 15 (5.2%), 16 (7.4%), 17 (8.9%), 18 (Nd), 19 (6.7%), 20 (7.2%), 21 (2.4%), 22 (1.9%), 23 (2.4%), 24 (6.0%), 25 (14.8%), 26 (3.3%), 27 (1.0%), 28 (4.4%), 29 (6.8%), 30 (10.6%), 31 (4.9%), 32 (9.6%), 33 (4.6%), 34 (4.2%), 35 (4.0%), 36 (3.3%), 37 (4.2%), 38 (3.2%), 39 (5.9%), 40 (7.5%), 41 (5.3%), 42 (3.4%), 43 (2.7%), 44 (3.5%), 45 (2.4%), 46 (3.7%), 47 (2.6%), 48 (5.5%), 49 (0.9%), 50 (4.4%), 51 (5.5%), 52 (4.3%), 53 (5.8%), 54 (5.9%), 55 (Nd), 56 (8.4%), 57 (7.8%), 58 (5.5%), 59 (8.1%), 60 (6.5%), 61 (3.6%), 62 (10.7%), 63 (6.6%), 64 (9.0%) and 65 (9.9%). The extracts were stored in dark glass bottles and kept in a cool dark place. The first cytotoxicity experiment of the screening was carried out within the first month after preparing the extracts to avoid the possible degradation of active compounds. In the first cytotoxicity experiment, a stock solution of each extract was prepared in DMSO (100 mg/mL); a part of this solution was diluted in culture medium and immediately used to treat the cells. The stock solutions were aliquoted and frozen at -80ºC. The rest of independent cytotoxicity experiments were carried out using different aliquots to avoid freeze-thaw cycles.
Chemicals and cell lines
Cisplatin, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and resazurin were obtained from Sigma. MRC-5 (human lung fibroblastic cells) and A549 (human lung adenocarcinoma cells) were purchased from European Collection of Cell Cultures. PC3 (human prostate cancer cells), MCF7 (human breast cancer cells), HeLa (human cervical carcinoma cells), NB4 (human acute promyelocytic leukemica cells), HL-60 (human acute promyelocytic leukemia cells), HepG2 (human hepatocellular carcinoma cells), SW480 (human colon adenocarcinoma cells) and U2OS (human osteosarcoma cells) were kindly provided by Dr. Helleday (Karolinska Institute, Sweden). BJ-hTERT (hTERT-immortalized foreskin fibroblast BJ cells), BJ-SV40T (SV40T-transformed BJ-hTERT cells), and BJ-RASV12 (H-RAS V12-transformed BJ-SV40T cells) were generously provided by Dr. Hahn (Dana-Farber Cancer Institute, USA) [10] . MRC-5, A549, MCF7, HeLa, HepG2, SW480, U2OS, BJ-hTERT, BJ-SV40T and BJ-RASV12 were cultured in DMEM high glucose medium (Gibco). PC3 was grown in DMEM-F12 (Gibco). HL60 and NB4 were grown in RPMI 1640 (Gibco). All media were supplemented with 100 U/mL penicillin, and 100 μg/mL streptomycin and 10% fetal bovine serum. All cells were kept at 37°C in a humidified atmosphere containing 5% CO 2 . Cell culture reagents were purchased from Thermo Fisher Scientific.
Cell viability assays
Exponentially growing cells (3,000-5,000 cells per well) were seeded in 96-well plates and were allowed to grow during 24 h. The cells were then exposed to several concentrations of the extracts or the positive controls cisplatin and 5-fluorouracil. After a treatment period of 72 h, cell viability was estimated with the MTT assay or the resazurin assay [3, 11] The MTT assay is based on the ability of viable cells to convert the MTT compound (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) into an insoluble and purple formazan product. After an incubation period of the cells with the MTT and a solubilization step, the quantity of the colored product is measured with a plate reading spectrophotometer. Dead cells are metabolically inactive and cannot produce the colored product. Briefly, after the 72-h treatment period, the medium was removed, the cells were washed with PBS, and 125 μL MTT (1 mg/mL in medium) were added to each well. The plates were incubated for 4 hours to allow viable cells to transform the MTT compound into an insoluble formazan product. This insoluble compound was solubilized by adding 80 μL 20% SDS in 0.02M HCl to each well and by incubating the plates overnight at 37°C. Finally, optical densities were measured at 540 nm on a multi-well plate spectrophotometer reader.
The resazurin assay is a redox-based colorimetric or fluorometric assay based on the capacity of viable cells to reduce the blue compound resazurin into the pink, fluorescent and soluble product resorufin. The quantity of resorufin produced is proportional to the number of viable cells. After the 72-h treatment period, 100 μL resazurin in medium were added to each well (final concentration of 10 µg/mL) for 1 hour before reading the fluorescence intensity at 530/590 nm (excitation/emission) on a fluorescence microplate reader.
In both assays, cell viability was calculated as percentage in relation to untreated cells from at least three independent experiments. After estimating cell viability and calculating IC 50 values, results were expressed as mean ± standard error of the mean (SEM), and a t-test (paired, two tailed) was used for statistical analysis. A P value ˃0.05 is not considered statistically significant and is not represented by any symbol. A P value ≤0.05 is considered statistically significant and is represented with an asterisk, two asterisks (P ≤0.01) or three asterisks (P ≤0.001). Since selectivity is the most relevant parameter to detect anticancer potential in vitro [2] [3] [4] selectivity indices were used to quantify this parameter. The selectivity index (S.I.) was calculated as the average of the IC 50 value in the normal cell line (MRC-5) divided by the IC 50 value in the cancer cell line (A549) obtained in each independent experiment [3] .
Results and Discussion
Because patients with metastatic cancers need selective anticancer treatments, we have prepared 65 extracts from 45 plants collected in Andalusia and we have used lung cancer cells (A549) and lung normal cells (MRC-5) to screen the extracts for selective cytotoxicity with the MTT assay. Table 1 shows the botanical names, families and other pertinent information on the 45 plant species. It also shows an identification number for each extract, the IC 50 value for both cell lines and the selectivity index. Doseresponse curves for the 65 extracts are provided in Figures 1S-6S (Supporting Information). Results show that several extracts induced selective cytotoxicity towards the cancer cell line, including the extract from the leaves of Cascabela thevetia (L.) Lippold (Apocynaceae) (10), the extract from the leaves of Digitalis purpurea L. (Plantaginaceae) (18), the extract from the bark of Frangula alnus Mill. (Rhamnaceae) (27), the extract from the whole plant Iberis ciliata subsp. contracta (Pers.) Moreno (Brassicaceae) (37), the extract from the seeds of Juniperus macrocarpa Sm. (Cupressaceae) (39), the extract from the bulb of Pancratium maritimum L. (Amaryllidaceae) (46), and the extract from the leaves of Tetraclinis articulata (Vahl) Mast. (Cupressaceae) (58). The anticancer drugs cisplatin and 5-fluorouracil, and an extract form the leaves of Taxus baccata L. (Taxaceae) (57) also showed selectivity against the cancer cells ( Table 1 ). The extract from the leaves of Tetraclinis articulata (Vahl) Mast. (58) showed the most relevant activity; it was more cytotoxic against the lung cancer cells (IC 50 = 0.37 ± 0.03 µg/mL) than against the lung normal cells (IC 50 = 129.5 ± 64.0 µg/mL), displaying a selectivity index of 378.3. The extract from the leaves of Taxus baccata L. (Taxaceae) was also more cytotoxic against the lung cancer cells (IC 50 = 0.86 ± 0.27 µg/mL) than against the lung normal cells (IC 50 = 146.9 ± 87.8 µg/mL), displaying a selectivity index of 157.3.
Extracts 10, 18, 37, 46, 57 and 58, and the anticancer agents cisplatin and 5-fluorouracil, were tested with the resazurin assay against eleven additional cell lines: 2 leukemia cell lines, 6 cancer cell lines derived from solid tumors of different tissues (liver, colon, bone, cervix, prostate and breast) and three genetically modified skin cell lines with increasing degree of malignancy (Table 2 and Figure 7S 
